TransCode Therapeutics Receives $2 Million Grant from NIH
BOSTON — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneering company in RNA oncology focused on enhancing cancer treatments, has secured a substantial $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This funding will support the clinical evaluation of TTX-MC138, the company’s leading therapeutic candidate aimed at combating advanced solid tumors. TransCode has initiated three clinical trial sites to commence a Phase I/II trial specifically designed to evaluate the safety of TTX-MC138.
Details and Objectives of the Clinical Trial
The ongoing clinical trial marks a vital milestone for TransCode as it aims to collect important data regarding the safety profile of TTX-MC138. While the primary focus of the trial is not on assessing efficacy, there is potential for early signs of clinical activity among patients with metastatic cancer. This grant funding is anticipated to be allocated over a two-year period, highlighting the NIH's commitment to fostering innovative research in oncology.
Leadership Insights
Dr. Zdravka Medarova, the Chief Scientific Officer at TransCode, expressed her appreciation for this recognition from the NIH. "We are honored that the NIH acknowledges our mission to advance therapies aimed at metastatic cancer," she remarked. Dr. Medarova emphasized the rigorous evaluation process that grants undergo, indicating that this achievement reflects the significant potential and innovation within the TTX-MC138 clinical development program.
Overview of TTX-MC138 and Its Innovations
TTX-MC138 is distinguished as a groundbreaking therapeutic candidate that addresses the unique challenges associated with treating metastatic disease. By focusing on tumors that overexpress microRNA-10b, a well-known marker of metastasis, TransCode aims to offer new hope for patients facing these aggressive cancer types. The strategy behind TTX-MC138 leverages TransCode's advanced TTX nanoparticle delivery platform, which is designed to enhance the effectiveness of RNA therapeutics.
Dedication to Advanced Cancer Therapies
TransCode Therapeutics is committed not only to the development of TTX-MC138 but is also actively pursuing a range of first-in-class RNA therapeutic candidates. These innovative solutions are intended to address the complexities of RNA delivery and broaden therapeutic options across various cancer types. The research and development efforts at TransCode reflect its steadfast commitment to transforming cancer treatment paradigms.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to TransCode?
The NIH grant will support the clinical evaluation of TTX-MC138, focusing on its safety in treating metastatic cancer.
How will the clinical trial design benefit TransCode?
The trial is structured to generate crucial safety data and may offer early signs of clinical activity despite not being focused on efficacy.
Who is leading the research at TransCode Therapeutics?
Dr. Zdravka Medarova serves as the Chief Scientific Officer, overseeing the development of TTX-MC138.
What is TTX-MC138 designed to treat?
TTX-MC138 is developed to treat advanced solid tumors that have an overexpression of microRNA-10b.
What sets TTX-MC138 apart from other treatments?
TTX-MC138 represents a first-in-class therapy targeting metastatic disease, utilizing an innovative RNA nanoparticle delivery system.
